$16.17 1.6%
Price vs. AI Score (Last 150 days)
Data gathered: March 5

AI Score

Sign up to see AI score

Brand Score Sign up
Employment Score Sign up
User Growth Score Sign up
Fundamental Score Sign up

Data Bits

Data Bits Value / Change Benchmark
Job Posts 71 0%
Sentiment 77 0%
Webpage traffic 38,000 6.3%
Employee Rating 63 0%
Google Trends 0%
Patents 195 0%
4chan Mentions 0% N/A
Reddit Mentions 0%
Stocktwits Mentions 3 0%
Stocktwits Subscribers 7,251 -0%
Twitter Followers 2,627 -0%
Twitter Mentions 21 10.5%
News Mentions -100%
Customer reviews 0%
ESG 45 -2.2%
Business outlook 32 0%
Linkedin Employees 1,388 N/A

About NovoCure

NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. The company markets Optune and Optune Lua, a Tumor Treating Fields delivery system for use as a monotherapy treatment for adult patients with glioblastoma.

Price $16.17
Target Price Sign up
Volume 22,300
Market Cap $1.74B
Year Range $11.13 - $82.51
Dividend Yield 0%
Revenue per Employee $385,862
Industry Medical & Dental Instruments

In the news

Financial performance View All

Revenue Cost of Revenue Gross Profit Net Income ebitda EPS
Q4 '23134M33M101M-47M-15M-0.450
Q3 '23127M32M95M-49M-52M-0.460
Q2 '23126M34M92M-57M-56M-0.540
Q1 '23122M30M93M-53M-52M-0.500
Q4 '22128M29M100M-37M-23M-0.360

Insider Transactions View All

GROENHUYSEN WILHELMUS CM filed to sell 254,559 shares at $16.1.
February 29 '24
Leonard Frank X filed to sell 162,617 shares at $16.1.
February 29 '24
Shah Pritesh filed to sell 124,511 shares at $12.7.
November 8 '23
Shah Pritesh filed to sell 124,893 shares at $21.8.
September 5 '23
GROENHUYSEN WILHELMUS CM filed to sell 209,825 shares at $21.8.
September 5 '23

What is the Market Cap of NovoCure?

The Market Cap of NovoCure is $1.74B.

How Many People Work at NovoCure?

As of our latest update, NovoCure employed approximately 1,320 people worldwide. However, it's important to note that NovoCure's workforce size can fluctuate due to the company's growth, restructuring, or strategic shifts, so the current number of employees may be different.

What is NovoCure's revenue per employee?

$385,862. To calculate NovoCure's revenue per employee, we divide the company's total revenue in the last 4 quarters by its total number of employees.

What is the current price of NovoCure?

Currently, the price of one share of NovoCure is $16.17.

How can I analyze the NVCR stock price chart for investment decisions?

The NVCR stock price chart above provides a comprehensive visual representation of NovoCure's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling NovoCure shares. Our platform offers an up-to-date NVCR stock price chart, along with technical data analysis and alternative data insights.

Does NVCR offer dividends to its shareholders?

As of our latest update, NovoCure (NVCR) does not offer dividends to its shareholders. Investors interested in NovoCure should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.

What are some of the similar stocks of NovoCure?

Some of the similar stocks of NovoCure are Align Technology, Dentsply, LeMaitre Vascular, iRhythm Technologies, and Silk Road Medical.

The analytics provided are estimates and not a substitute for professional advice. All investments involve risks, including possible capital loss.
About Us

AltIndex revolutionizes investing with advanced alternative data analytics, smart insights, and stock alerts, presented in an easy-to-use dashboard powered by comprehensive company data from across the internet.

Legal Disclaimer
The information provided by AltIndex is solely for informational purposes and not a substitute for professional financial advice. Investing in financial markets carries inherent risks, and past performance doesn't guarantee future results. It's crucial to do your research, consult with financial experts, and align your financial objectives and risk tolerance before investing. AltIndex creators and operators are not liable for any financial losses incurred from using this information. Users should exercise caution, seek professional advice, and be prepared for the risks involved in trading and investing in financial assets, only investing what they can afford to lose. The information in this application, derived from publicly available data, is believed to be reliable but may not always be accurate or current. Users should verify information independently and not solely rely on this application for financial decisions. By using AltIndex, you acknowledge that it doesn't offer financial advice and agree to consult a qualified financial advisor before making investment decisions.

© 2024 AltIndex. All rights reserved.